Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature

References

• Wintrobe MM, Buell MV. Hyperproteinemia associated with multiple myeloma. Bull Johns Hopkins Hosp 1933;52:156.
   Google Scholar
• Von Bonsdorff B, Groth H, Packalen T. On the presence of a high-molecular crystallizable protein in the blood serum in myeloma. Folia Haematol 1938;59:184.
   Google Scholar
• Brouet JC, Clauvel JP, Danon F, . Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775–788.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Barate C, Minola E, . Cryoglobulinemia. Blood Rev 2007;21:183–200.
   PubMed Web of Science ®Google Scholar
• Rieu V, Cohen P, André MH, . Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology 2002;41:290–300.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Mitterer M, Gunsilius E. Bortezomib for the treatment of refractory type-1 cryoglobulinaemia. Br J Haematol 2010;150: 235–237.
   PubMed Web of Science ®Google Scholar
• Ninomiya S, Fukuno K, Kanemura N, . Ig G type multiple myeloma and concurrent Ig A type monoclonal gammapathy of undetermined significance complicated by necrotizing skin ulcers due to type I cryoglobulinemia. J Clin Exp Hematopathol 2010;50: 71–74.
   PubMedGoogle Scholar
• Cohen SJ, Pittelkow MR, Su WP. Cutaneous manifestations of cryoglobulinemia: clinical and histopathological study of seventy-two patients. J Am Acad Dermatol 1991;25:21–27.
   PubMed Web of Science ®Google Scholar
• Monti G, Galli M, Invernizzi F, . Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995;88:115–126.
   PubMed Web of Science ®Google Scholar
• Trejo O, Ramos-Casals M, García-Carrasco M, . Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001;80: 252–262.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A. Symptomatic cryoglobulinemia. Curr Treat Options Oncol 2000;2:105–118.
   Google Scholar
• Vila AT, Barnadas MA, Ballarin J, . Cutaneous ulcers with type I cryoglobulinemia treated with plasmapheresis. Eur J Dermatol 2004;14:186–189.
   PubMed Web of Science ®Google Scholar
• Chan AOK, Lau JSM, Chan CH, . Cryoglobulinaemia: clinical and laboratory perspectives. Hong Kong Med J 2008;14:55–59.
   PubMedGoogle Scholar
• Requena L, Kutzner H, Angulo J, . Generalized livedo reticularis associated with monoclonal cryoglobulinemia and multiple myeloma. J Cutan Pathol 2007;34:198–202.
   PubMed Web of Science ®Google Scholar
• Dotten DA, Pruzanski W, Olin J, . Cryocrystalglobulinemia. Can Med Assoc J 1976;114:909–912.
   PubMed Web of Science ®Google Scholar
• Aster J. Multiple myeloma and related plasma cell dyscrasias. In: Cotran RS, Kumar V, Robbins SL, editors. Robbin's basic pathology. Philadelphia: W. B. Saunders; 2003.
   Google Scholar
• Kyle RA. Plasma cell disorders. In: Goldman L, Bennett JC, editors. Cecil textbook of medicine. Singapore: Harcourt Asia Pte Ltd; 2000, p693–703.
   Google Scholar
• Longo DL. Plasma cell disorders. In: Kasper DL, Fauci AS, Longo DL, ., editors. Harrison's principles of internal medicine. New York: McGraw-Hill; 2001. pp
   Google Scholar
• Ansari NA, Owais M, Usha. Immunoglobulin heavy and light chain isotypes in multiple myeloma patients. Asian Pac J Cancer Prev 2007;8:593–596.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3–9.
   PubMed Web of Science ®Google Scholar
• Aarset H, Dekker J, Brorson SH, . Crystal-induced arthritis mimicking rheumatoid arthritis in a patient with monoclonal gammopathy. Arthritis Rheum 2002;46:2816.
   PubMedGoogle Scholar
• Molloy C, Peck R, Bonny S, . An unusual presentation of multiple myeloma: a case report. J Med Case Rep 2007;1:84.
   Google Scholar
• Ardalan MR, Shoja MM. Multiple myeloma presented as acute interstitial nephritis and rheumatoid arthritis-like polyarthritis. Am J Hematol 2007;82:309–313.
   PubMed Web of Science ®Google Scholar
• Jorgensen C, Guerin B, Ferrazzi V, . Arthritis associated with monoclonal gammapathy: clinical characteristics. Br J Rheumatol 1996;35:241–243.
   PubMedGoogle Scholar
• Langlands DR, Dawkins RL, Matz LR, . Arthritis associated with a crystallizing cryoprecipitable IgG paraprotein. Am J Med 1980;68:461–465.
   PubMed Web of Science ®Google Scholar
• Marcus RL, Townes AS. The occurrence of cryoproteins in synovial fluid; the association of a complement-fixing activity in rheumatoid synovial fluid with cold-precipitable protein. J Clin Invest 1971;50: 282–293.
   PubMed Web of Science ®Google Scholar
• Pecondon-Espanol A, Giraldo-Castellano P. Erosive seronegative arthritis associated with monoclonal gammopathy in Spanish. Med Clin (Barc) 2003;120:278–279.
   PubMed Web of Science ®Google Scholar
• Vitali C, Baglioni P, Vivaldi I, . Erosive arthritis in monoclonal gammopathy of uncertain significance: report of four cases. Arthritis Rheum 1991;34:1600–1605.
   PubMed Web of Science ®Google Scholar
• Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci 2010;42:247–251.
   PubMed Web of Science ®Google Scholar
• McGovern TW, Enzenauer RJ, Fitzpatrick JE. Treatment of recalcitrant leg ulcers in cryoglobulinemia types I and II with plasmapheresis. Arch Dermatol 1996;132:498–500.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Ara G, Herbst R, . The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638–2645.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10: 361–369.
   PubMedGoogle Scholar
• Roccaro AM, Hideshima T, Raje N, . Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184–191.
   PubMed Web of Science ®Google Scholar
• Kern J, Untergasser G, Zenzmaier C, . GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood 2009;114:3960–3967.
   PubMed Web of Science ®Google Scholar
• Talamo G, Claxton D, Tricot G, . Response to bortezomib in refractory type I cryoglobulinemia. Am J Hematol 2008;83:883–884.
   PubMed Web of Science ®Google Scholar
• Li J, Zhou DB, Jiao L, . Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma 2009;9:394–398.
   PubMedGoogle Scholar
• Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139–3146.
   PubMed Web of Science ®Google Scholar
• Vermeersch P, Gijbels K, Marien G, . A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem 2008;54:39–43.
   PubMed Web of Science ®Google Scholar
• Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520–2530.
   PubMed Web of Science ®Google Scholar